UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen

Leukemia & lymphoma, 2018-04, Vol.59 (4), p.931-940

2018

Volltextzugriff (PDF)

Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function

Journal of immunological methods, 2004-10, Vol.293 (1), p.127-142

2004

Volltextzugriff (PDF)

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

Journal of dermatology, 2010-05, Vol.37 (5), p.413-425

2010

Volltextzugriff (PDF)

Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study

Cancer treatment and research communications, 2020, Vol.25, p.100235-100235, Article 100235

2020

Volltextzugriff (PDF)

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.455-455

2023

Volltextzugriff (PDF)

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1933-1933

2023

Volltextzugriff (PDF)

Abstract 365: High throughput screen to evaluate combinations with ibrutinib in various B-cell malignancies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.365-365

2016

Volltextzugriff (PDF)

Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry

Journal of immunological methods, 2011-01, Vol.363 (2), p.158-165

2011

Volltextzugriff (PDF)

Effects of Ibrutinib on Rituximab and GA-101 Induced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro

Blood, 2014-12, Vol.124 (21), p.3117-3117

2014

Volltextzugriff (PDF)

Biomarker Analysis in a Phase Ib Study Combining Ibrutinib with R-CHOP in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)

Blood, 2014-12, Vol.124 (21), p.2965-2965

2014

Volltextzugriff (PDF)

Abstract B18: Quantification of BTK engagement by ibrutinib in peripheral blood mononuclear cells in a phase I clinical study

Clinical cancer research, 2015-09, Vol.21 (17_Supplement), p.B18-B18

2015

Volltextzugriff (PDF)

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Blood, 2014-12, Vol.124 (21), p.78-78

2014

Volltextzugriff (PDF)

Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Cellular immunology, 2007-05, Vol.247 (1), p.1-11

2007

Volltextzugriff (PDF)

Abstract 2215: Pharmacogenomic investigation of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765): drug sensitivity in diffuse large B-cell lymphoma (DLBCL) within a tumor microenvironment-aligned high-throughput screen

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2215-2215

2013

Volltextzugriff (PDF)

Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry: Flow Cytometry-based Biomarkers in Translational Medicine and Drug Development

Journal of immunological methods, 2011, Vol.363 (2), p.158-165

2011

Volltextzugriff (PDF)

Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (β1 and β2), IL-2Rα, and CXCR3

Cellular Immunology, 2005-07, Vol.236 (1), p.131-139

2005

Volltextzugriff (PDF)

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Cellular immunology, 2007-05, Vol.247 (1), p.1-11

2007

Volltextzugriff (PDF)

Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (beta1 and beta2), IL-2Ralpha, and CXCR3

Cellular immunology, 2005-07, Vol.236 (1-2), p.131-139

2005

Volltextzugriff (PDF)

Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes

Cellular Immunology, 2005-07, Vol.236 (1), p.123-130

2005

Volltextzugriff (PDF)

T‐Cell Surface Markers in Human Peripheral Whole Blood Using Flow Cytometry

Validation of Cell‐Based Assays in the GLP Setting, 2008, p.85-105

2008

Volltextzugriff (PDF)

Flow Cytometric Cell‐Based Assays: An Overview of General Applications

Validation of Cell‐Based Assays in the GLP Setting, 2008, p.73-83

2008

Volltextzugriff (PDF)

Coronavirus Disease Contact Tracing Outcomes and Cost, Salt Lake County, Utah, USA, March–May 2020

Emerging infectious diseases, 2021-12, Vol.27 (12), p.2999-3008

2021

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)
Buchkapitel
(2)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen

Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Abstract 365: High throughput screen to evaluate combinations with ibrutinib in various B-cell malignancies

Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry

Effects of Ibrutinib on Rituximab and GA-101 Induced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro

Biomarker Analysis in a Phase Ib Study Combining Ibrutinib with R-CHOP in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)

Abstract B18: Quantification of BTK engagement by ibrutinib in peripheral blood mononuclear cells in a phase I clinical study

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Abstract 2215: Pharmacogenomic investigation of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765): drug sensitivity in diffuse large B-cell lymphoma (DLBCL) within a tumor microenvironment-aligned high-throughput screen

Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry: Flow Cytometry-based Biomarkers in Translational Medicine and Drug Development

Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (β1 and β2), IL-2Rα, and CXCR3

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (beta1 and beta2), IL-2Ralpha, and CXCR3

Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes

T‐Cell Surface Markers in Human Peripheral Whole Blood Using Flow Cytometry

Flow Cytometric Cell‐Based Assays: An Overview of General Applications

Coronavirus Disease Contact Tracing Outcomes and Cost, Salt Lake County, Utah, USA, March–May 2020

Suchergebnisse filtern